Abbott India Ltd SHARE PRICE [LIVE]

About ABBOTINDIA

Today's live share price for Abbott India Ltd is NSE: ₹ 21,278.25, BSE: ₹ 21,182.45 with a current market capitalization of .

Abbott India Ltd is one of the largest MNC pharma company operating in India. The Company is engaged in the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. They are having their presence in both OTC drugs and formulations. Their manufacturing facilities are located at Verna in Goa. The company's global products include Brufen, Prothiaden, Thyronorm and Leptos. The company has four divisions. The Primary Care division markets products in the areas of pain management and gastroenterology. The Specialty Care-Methabolics and Urology division provides solutions in the areas of thyroid, obesity, diabetes and benign prostatic hyperplasia. The Specialty Care-Neuroscience division has a varied portfolio with specialty products in neurology and psychiatric segments. Hospital Care offers products in the field of anesthesiology and neonatology, such as Forane, Sevorane and Survanta. Abbott India Ltd was originally incorporated on August 22, 1944 as Boots Pure Drug Company (India) Ltd. The company name was changed to The Boots Company (India) Ltd on November 1, 1971, thereafter to Boots Pharmaceuticals Ltd on January 1, 1991. In October 31, 1995 the name was changed to Knoll Pharmaceuticals Ltd, and in July 1, 2002, they got their present name Abbott India Ltd. In the year 2002, the company sold their Jejuri Undertakings together with assets and liabilities as a going concern. In the year 2003, the company's wholly owned subsidiary company, Lenbrook Pharmaceuticals Ltd was amalgamated with the company. In the year 2004, the company started the production of Capsules with the capacity of 27 Millions Nos. In the year 2005, they further increased the capacity to 56 Million Nos. Also, they started a new project of producing Nutritional Products with the installed capacity of 600 Tonnes. In the year 2006, the company increased the production capacity of Tablets by 236 Million Nos to 686 Million Nos. In the year 2008, they further increased the production capacity of Tablets by 769 million Nos to 1455 million Nos. They launched Digene Total, buffered pantoprazole tablet for quick and sustained antacid action and Brugel a novel formulation for sprains and strains. Also, they launched Thyronorm 150, Digene Sugar Free Tablet and Gel during the year. The company acquired Solvay Pharmaceuticals, pursuant to which Solvay became a part of Abbott's global Pharmaceutical Products Group.